Deep Brain Stimulation Shows Promise in Drug-Resistant Epilepsy: FRANCE Trial Findings
France: A new randomized clinical trial has explored the role of deep brain stimulation (DBS) targeting the anterior nucleus of the thalamus (ANT) in patients with drug-resistant epilepsy (DRE), suggesting that this approach may offer meaningful seizure reduction in individuals who have exhausted conventional treatment options. The findings were published in Epilepsia by Stéphan Chabardès and colleagues from Grenoble Alpes University Hospital.
Drug-resistant epilepsy remains a significant clinical challenge, particularly for patients who do not respond to anti-seizure medications or interventions such as vagus nerve stimulation (VNS). While DBS has emerged as a potential therapeutic strategy, its comparative effectiveness against best medical treatment (BMT) in such patients has not been well established. To address this gap, researchers conducted a phase 3, open-label, randomized controlled trial across 14 specialized epilepsy and DBS centers.
The study enrolled 61 adults with focal or multifocal DRE who had previously not benefited from VNS therapy. Participants were randomly assigned to receive either continuous bilateral ANT-DBS along with standard care or to continue with best medical treatment, including VNS, for a duration of 12 months. Following this phase, patients in the medical therapy group were offered DBS and monitored for an additional year.
The trial revealed the following findings:
- At 12 months, patients receiving DBS showed a greater median reduction in severe monthly seizure frequency compared to those on medical therapy alone.
- Around 45% of patients in the DBS group achieved at least a 50% reduction in seizure frequency, compared to 27% in the best medical treatment group, though this difference was not statistically significant.
- Within-group analysis demonstrated that seizure reduction in the DBS group was significant and sustained at both 12 and 24 months.
- Patients who crossed over from medical therapy to DBS also experienced notable reductions in seizure frequency after one year of stimulation.
- No significant differences in quality of life were observed between the DBS and medical therapy groups during the study period.
- The safety profile of anterior nucleus of the thalamus DBS was favorable, with no major device-related adverse events reported.
- These findings support the consideration of DBS as a treatment option for patients with severe, treatment-resistant epilepsy.
The authors note that the study was limited by its relatively small sample size, which may have reduced its ability to detect statistically significant differences between groups. Additionally, the response observed in the medical therapy group was higher than expected, further complicating direct comparisons. As a result, while the findings point toward a beneficial effect of DBS, they do not conclusively establish its superiority over best medical therapy.
Overall, the FRANCE study suggests that ANT-DBS can offer clinically meaningful seizure reduction in a subset of patients with drug- and VNS-resistant epilepsy. Given its favorable safety profile and sustained within-group benefits, DBS may serve as a valuable palliative option in this difficult-to-treat population. Further large-scale studies are needed to better define its role and optimize patient selection.
Reference:
Chabardès, S., Bartolomei, F., Nica, A., Haegelen, C., Minotti, L., Piallat, B., Mosca, C., Massicot, S., Rheims, S., Guenot, M., Cuny, E., Aupy, J., Maillard, L., Colnat-Coulbois, S., Leroy, C., Carron, R., Coubes, P., Gélisse, P., Karachi, C., . . . Regis, J. Deep brain stimulation of the thalamus for intractable epilepsy (FRANCE study): A randomized clinical trial. Epilepsia. https://doi.org/10.1002/epi.70211
Next Story